Expertise in
26
conditions

Dr. Preston D. Steen

Internal Medicine
Sanford Clinic North
820 4th St N, 
Fargo, ND 
Clinical Trials:Currently Recruiting for 3 Trials
Expertise in
26
conditions
Sanford Clinic North
820 4th St N, 
Fargo, ND 

Overview

Preston Steen is a primary care provider, practicing in Internal Medicine in Fargo, North Dakota.

Dr. Steen is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 173 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in ND

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HealthPartners
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO

Locations

Sanford Clinic North
820 4th St N, Fargo, ND 58102

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

170 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Other
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Suspended
Publish Date: September 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 7 Less Clinical Trials

12 Total Publications

Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network.
Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 27, 2024
Similar Doctors
Expertise in
12
conditions
Dr. Harminder D. Singh
Internal Medicine
Expertise in
12
conditions
Dr. Harminder D. Singh
Internal Medicine

Sanford Medical Center Fargo

5225 23rd Ave S, 
Fargo, ND 
 (6.9 miles away)
701-417-2575
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients

Harminder Singh is a primary care provider, practicing in Internal Medicine in Fargo, North Dakota. Dr. Singh is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Hemorrhagic Proctocolitis, Ulcerative Colitis, Colonoscopy, and Endoscopy. Dr. Singh is currently accepting new patients.

Expertise in
29
conditions
Dr. Aaron R. Robertson
Internal Medicine
Expertise in
29
conditions
Dr. Aaron R. Robertson
Internal Medicine

Cobalt Rehabilitation Hospital Fargo LLC

4671 38th St S, 
Fargo, ND 
 (6.9 miles away)
701-404-5100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aaron Robertson is a primary care provider, practicing in Internal Medicine in Fargo, North Dakota. Dr. Robertson is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Necrotizing Myopathy (NM), Hypertensive Heart Disease, End-Stage Renal Disease (ESRD), Endoscopy, and Gastrostomy. Dr. Robertson is currently accepting new patients.

Expertise in
20
conditions
Dr. Michael S. Sheldon
Internal Medicine
Expertise in
20
conditions
Dr. Michael S. Sheldon
Internal Medicine
Before you request

Essentia Health-South University Clinic (Fargo)

1702 University Dr S, 
Fargo, ND 
 (2.2 miles away)
701-205-0094
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Sheldon is a primary care provider, practicing in Internal Medicine in Fargo, North Dakota. Dr. Sheldon is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Hypertension, and Maturity Onset Diabetes of the Young. Dr. Sheldon is currently accepting new patients.

Frequently Asked Questions about Dr. Preston D. Steen

How do I make an appointment with Dr. Preston D. Steen?

You can book an appointment with Dr. Preston D. Steen by calling their office at 320-839-2502. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Preston D. Steen a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Preston D. Steen is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Preston D. Steen specialize in?

While Dr. Preston D. Steen is a Internal Medicine, they have specific expertise in Colorectal Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Preston D. Steen participate in research or clinical trials?

Yes. Dr. Preston D. Steen has published 12 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Preston D. Steen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Preston D. Steen accept my insurance?

Dr. Preston D. Steen accepts most major insurance plans, including HealthPartners and Medica. We recommend calling the office directly at 320-839-2502 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Steen's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 124 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile